As a result, we found the enrichment of three oncogenic signatures gene sets in the high-risk group, including “JAK2_DN.V1_DN,” “MTOR_UP.N4.V1_DN,” and “CSR_EARLY_UP.V1_DN” (significant at FDR Q − value < 25% and nominal P value < 1%) (Figure 7 and Table S3), which suggests a crucial role in lung adenocarcinoma progression and prognosis of these significantly enriched gene sets. The gene discussed is JAK2; the disease is lung adenocarcinoma.